Innoviva logo

Innoviva

INVA | NASDAQ
Chart Builder DCF Calculator
$18.49
-$0.54 (-2.84%)
At close: Nov 16, 2026, 4:00 PM ET
$18.49
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.84%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
67.9
-1.0 pts
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #72/1021 (Top 7%)

Key Statistics

Market Data

Market Cap $1.31B
1D Range
18.41 19.24
52W Range
18.41 24.24

Valuation (TTM)

PE 9.29
PB 1.16
EV/EBITDA 1.71

Valuation (NTM)

Forward PE 22.13
Forward PEG -0.14
Price Target $34.00
Loading financial charts...

Profile

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily co...

Sector Healthcare
Industry Biotechnology
Employees 159
IPO Date Oct 5, 2004
Fiscal Year January - December

Latest News

Is Innoviva (INVA) Stock Undervalued Right Now?

6 days ago · zacks.com

Is Innoviva (INVA) Stock Undervalued Right Now?
INVA or MRK: Which Is the Better Value Stock Right Now?

8 days ago · zacks.com

INVA or MRK: Which Is the Better Value Stock Right Now?
Innoviva (INVA) Tops Q3 Earnings Estimates

12 days ago · zacks.com

Innoviva (INVA) Tops Q3 Earnings Estimates
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

29 days ago · businesswire.com

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Do Options Traders Know Something About Innoviva Stock We Don't?

1 month ago · zacks.com

Do Options Traders Know Something About Innoviva Stock We Don't?
INVA vs. MRK: Which Stock Is the Better Value Option?

1 month ago · zacks.com

INVA vs. MRK: Which Stock Is the Better Value Option?
Should Value Investors Buy Innoviva (INVA) Stock?

1 month ago · zacks.com

Should Value Investors Buy Innoviva (INVA) Stock?
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

3 months ago · seekingalpha.com

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

3 months ago · zacks.com

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Nortiva Bio Launches to Develop Long-Acting Oral Medicines

5 months ago · businesswire.com

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$1.03
Miss -300.00%
REV
$106.12M
Miss -7.97%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$34.00
Upside
+83.88%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.